MiNK Therapeutics, Eli Lilly and Company, Verona Pharma PLC American Depositary Share, Thermo Fisher Scientific, AbbVie, Pfizer, and Merck & Co., Inc. are the seven Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are publicly traded shares of companies involved in researching, developing, manufacturing, and marketing medications and medical treatments. By buying these stocks, investors gain exposure to the pharmaceutical sector’s financial performance, which is driven by factors such as clinical trial results, regulatory approvals, patent lifecycles, and global healthcare demand. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.
MiNK Therapeutics (INKT)
MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.
Shares of INKT stock traded up $56.44 on Friday, reaching $64.17. The company's stock had a trading volume of 47,688,147 shares, compared to its average volume of 205,097. MiNK Therapeutics has a 12-month low of $4.56 and a 12-month high of $76.00. The company has a market capitalization of $256.04 million, a P/E ratio of -25.46 and a beta of 0.19. The stock's 50 day simple moving average is $8.45 and its 200-day simple moving average is $8.47.
Read Our Latest Research Report on INKT
Eli Lilly and Company (LLY)
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.
Shares of LLY stock traded up $2.69 on Friday, reaching $793.34. The company's stock had a trading volume of 2,851,585 shares, compared to its average volume of 3,675,715. The company has a quick ratio of 1.06, a current ratio of 1.37 and a debt-to-equity ratio of 2.18. Eli Lilly and Company has a 12-month low of $677.09 and a 12-month high of $972.53. The company has a market capitalization of $751.88 billion, a P/E ratio of 64.55, a PEG ratio of 1.16 and a beta of 0.40. The stock's 50 day simple moving average is $766.39 and its 200-day simple moving average is $800.02.
Read Our Latest Research Report on LLY
Verona Pharma PLC American Depositary Share (VRNA)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Shares of VRNA stock traded down $0.02 on Friday, reaching $104.83. The company's stock had a trading volume of 10,916,452 shares, compared to its average volume of 1,593,486. The company has a quick ratio of 8.73, a current ratio of 8.86 and a debt-to-equity ratio of 1.07. Verona Pharma PLC American Depositary Share has a 12-month low of $18.51 and a 12-month high of $104.99. The company has a market capitalization of $8.50 billion, a P/E ratio of -52.42 and a beta of 0.24. The stock's 50 day simple moving average is $83.89 and its 200-day simple moving average is $67.82.
Read Our Latest Research Report on VRNA
Thermo Fisher Scientific (TMO)
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Shares of TMO stock traded up $4.29 on Friday, reaching $435.02. The company's stock had a trading volume of 2,511,384 shares, compared to its average volume of 1,999,630. The company has a quick ratio of 1.38, a current ratio of 1.77 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific has a 12-month low of $385.46 and a 12-month high of $627.88. The company has a market capitalization of $164.22 billion, a P/E ratio of 25.51, a PEG ratio of 2.31 and a beta of 0.77. The stock's 50 day simple moving average is $409.39 and its 200-day simple moving average is $476.23.
Read Our Latest Research Report on TMO
AbbVie (ABBV)
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.
ABBV traded down $2.68 during trading on Friday, reaching $192.32. The stock had a trading volume of 4,990,162 shares, compared to its average volume of 6,311,659. The stock has a market cap of $339.71 billion, a PE ratio of 81.84, a PEG ratio of 1.28 and a beta of 0.48. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.64 and a current ratio of 0.76. AbbVie has a one year low of $163.81 and a one year high of $218.66. The business has a 50-day moving average of $187.01 and a 200-day moving average of $189.05.
Read Our Latest Research Report on ABBV
Pfizer (PFE)
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
PFE traded down $0.13 during trading on Friday, reaching $25.65. The stock had a trading volume of 34,838,317 shares, compared to its average volume of 41,846,522. The stock has a market cap of $145.83 billion, a PE ratio of 18.59, a PEG ratio of 0.94 and a beta of 0.58. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. Pfizer has a one year low of $20.92 and a one year high of $31.54. The business has a 50-day moving average of $23.89 and a 200-day moving average of $24.79.
Read Our Latest Research Report on PFE
Merck & Co., Inc. (MRK)
Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.
MRK traded down $0.67 during trading on Friday, reaching $83.35. The stock had a trading volume of 9,716,130 shares, compared to its average volume of 13,445,339. The stock has a market cap of $209.29 billion, a PE ratio of 12.13, a PEG ratio of 0.87 and a beta of 0.39. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.16 and a current ratio of 1.41. Merck & Co., Inc. has a one year low of $73.31 and a one year high of $129.03. The business has a 50-day moving average of $79.08 and a 200-day moving average of $86.40.
Read Our Latest Research Report on MRK
Further Reading
Before you consider MiNK Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MiNK Therapeutics wasn't on the list.
While MiNK Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
